bioAffinity Technologies, Inc. (BIAF)
9.82
-0.68
(-6.48%)
USD |
NASDAQ |
Sep 10, 12:28
bioAffinity Technologies Debt to Equity Ratio : 0.3808 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.3808 |
| March 31, 2026 | 0.3776 |
| December 31, 2025 | 0.1595 |
| September 30, 2025 | 0.0765 |
| June 30, 2025 | -0.3137 |
| March 31, 2025 | 0.9248 |
| December 31, 2024 | 0.5769 |
| September 30, 2024 | 0.5509 |
| June 30, 2024 | 0.402 |
| March 31, 2024 | 0.2843 |
| December 31, 2023 | 0.3251 |
| September 30, 2023 | 0.2411 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0052 |
| March 31, 2023 | 0.0174 |
| December 31, 2022 | 0.0228 |
| September 30, 2022 | 0.0647 |
| June 30, 2022 | -0.8729 |
| March 31, 2022 | -0.9405 |
| December 31, 2021 | -0.9675 |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | -0.9073 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Anika Therapeutics, Inc. | 0.1839 |
| Perspective Therapeutics, Inc. | 0.0122 |
| MiMedx Group, Inc. | 0.0797 |
| Veracyte, Inc. | 0.0289 |
| ABVC BioPharma, Inc. | 0.2807 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 7.619M |
| Total Liabilities (Quarterly) | 3.850M |
| Shareholders Equity (Quarterly) | 3.769M |
| Current Ratio | 1.442 |
| Net Debt Paydown Yield | -0.38% |